Treatment Selection: A Focus on Prognostic Indicators
Release Date: February 17, 2022
Expiration Date: February 17, 2023
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Acute myeloid leukemia is a disease of older individuals, with the median age of presentation being between 67 to 70 years of age. In this activity, Dr. Wang explains prognostic factors, including mutational profiling, and how they help determine if your patient is ‘fit’ or ‘unfit’ for intensive chemotherapy.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Discuss the limitations of clinical trial criteria used to differentiate patients who are ‘fit’ versus ‘unfit’ for intensive induction therapy
- Assess the role of performance status in determining patient fitness for intensive induction therapy
- Outline factors that increase the likelihood of therapeutic resistance
- Investigate the impact of comorbidity status on outcomes in both high- and low-intensity treatment groups
Treatment Selection: A Focus on Prognostic Indicators – Eunice S. Wang, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 17, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr. Eunice Wang earned her medical degree from the Keck (University of Southern California) School of Medicine. She completed her internal medicine residency at Yale-New Haven Hospital followed by hematology-oncology fellowship training at Memorial Sloan Kettering Cancer Center. She is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center. Dr. Wang directs the Roswell Park Hematological Procurement Shared Resource and is Physician Leader for the Roswell Park Chemotherapy/Infusion center. She also serves as an Associate Professor in the Department of Medicine, Jacobs School of Medicine, University of Buffalo.
Dr. Wang has an active clinical practice caring for patients with acute leukemias, myeloid malignancies, and other hematological disorders. Her clinical research program is focused on early phase clinical trials of novel therapies, particularly small molecular inhibitors and immunotherapy for acute leukemia and myeloid malignancies. She leads a translational laboratory investigating the role of the marrow microenvironment in acute myeloid leukemia. To date, she has authored/co-authored more 150 peer-reviewed clinical and translational research articles in hematological malignancies.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-001-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Eunice Wang has relevant financial relationships related to advisory activities and consulting from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Gilead, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, and Kite Pharma, as well as consulting from Astellas Pharma US, Inc., Novartis AG, Pfizer Inc., and PharmaEssentia Corporation. She is on speakers’ bureau for AbbVie, Astellas, DAVA Oncology, Kite, Stemline Therapeutics, Inc., Novartis, and Pfizer. Dr. Wang is also on the Data Safety Monitoring Boards of AbbVie, Gilead, and Rafael Pharmaceuticals, Inc.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.